for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sartorius Stedim Biotech SA

STDM.PA

Latest Trade

136.80EUR

Change

1.10(+0.81%)

Volume

64,788

Today's Range

135.00

 - 

137.00

52 Week Range

79.65

 - 

150.70

As of on the Euronext Paris ∙ Minimum 15 minute delay

Latest Developments

Sartorius Stedim Biotech 9-Month EBITDA Up At EUR 312.3 Mln

Oct 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::NINE-MONTH FIGURES FOR 2019: SARTORIUS STEDIM BIOTECH REPORTS DOUBLE-DIGIT SALES GROWTH.9-MONTH SALES REVENUE EUR 1,076.7M (+18.1%); ORDER INTAKE EUR 1,147.1M (+18.0%); UNDERLYING EBITDA MARGIN 29.0%.MANAGEMENT SPECIFIES REVENUE GUIDANCE AT UPPER END OF 12% TO 16% RANGE.9-MONTH UNDERLYING NET PROFIT FOR PERIOD AMOUNTED TO 198.1 MILLION EUROS, A 23.3% INCREASE YEAR OVER YEAR.GUIDANCE 2019 SPECIFIED AT UPPER END OF BANDWIDTH.9 MONTHS EBITDA EUR 312.3 MILLION VERSUS EUR 251.4 MILLION YEAR AGO.2019 OUTLOOK: UNDERLYING EBITDA MARGIN REMAINS PROJECTED TO RISE BY SLIGHTLY MORE THAN ONE PERCENTAGE POINT OVER THE PRIOR-YEAR FIGURE OF 28.2%.

Sartorius Stedim Biotech Signs Agreement To Acquire Parts Of Danaher Life Science

Oct 21 (Reuters) - Sartorius Stedim Biotech SA <STDM.PA>::SARTORIUS STEDIM BIOTECH SIGNS AGREEMENT TO ACQUIRE SELECT DANAHER LIFE SCIENCE PLATFORM BUSINESSES.PROPOSED TRANSACTION IS PART OF THE SALE OF A LARGER PORTFOLIO OF BUSINESSES FROM DANAHER TO SSB’S MAJOR SHAREHOLDER SARTORIUS GROUP.PROPOSED TRANSACTION IS EXPECTED TO BE COMPLETED IN Q1 OF 2020.AGREEMENT IS SUBJECT TO ACQUISITION OF THE GE BIOPHARMA BUSINESS BY DANAHER AND RELATED REGULATORY APPROVALS.TOTAL PURCHASE PRICE IS APPROXIMATELY $750 MILLION IN CASH OF WHICH ABOUT A QUARTER WILL BE ALLOCATED TO BUSINESSES PURCHASED BY SSB.

Sartorius Stedim Biotech H1 Underlying EBITDA At EUR 205.3 Mln

July 19 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::FIRST-HALF 2019 FIGURES: SARTORIUS STEDIM BIOTECH CONTINUES ON THE GROWTH TRACK.FIRST-HALF 2019 FIGURES: SARTORIUS STEDIM BIOTECH CONTINUES ON GROWTH TRACK.SARTORIUS STEDIM BIOTECH CONTINUES ON GROWTH TRACK.SALES REVENUE UP 19.0%; ORDER INTAKE UP 21.5%; EARNINGS MARGIN 28.STRONG GROWTH ACROSS ALL PRODUCT CATEGORIES AND GEOGRAPHIES.MANAGEMENT RAISES GUIDANCE FOR FULL YEAR OF 2019.UNDERLYING EBITDA ROSE OVERPROPORTIONATELY TO 205.3 MILLION EUROS.UNDERLYING EBITDA SHOWED A YEAR-OVER-YEAR INCREASE OF 26.2%.RESPECTIVE MARGIN INCREASED TO 28.9% (H1 2018: +27.8%), WITH AROUND HALF OF A PERCENTAGE POINT ATTRIBUTABLE TO CHANGE IN ACCOUNTING RULES.UNDERLYING NET PROFIT FOR PERIOD SURGED 26.4% FROM EUR 103.7 MILLION TO EUR 131.1 MILLION.THIS YIELDED UNDERLYING EARNINGS PER SHARE OF EUR 1.42 COMPARED WITH EUR 1.12 IN PRIOR-YEAR PERIOD.BASED ON BUSINESS PERFORMANCE SO FAR AND STRONG SECOND-HALF PROSPECTS, MANAGEMENT OF SARTORIUS STEDIM BIOTECH GROUP HAS RAISED ITS SALES FORECAST FOR FULL YEAR OF 2019.SALES REVENUE IS NOW EXPECTED TO INCREASE BY ABOUT 12% TO 16% VERSUS PREVIOUS GUIDANCE OF ABOUT 7% TO 11%.COMPANY'S UNDERLYING EBITDA MARGIN REMAINS PROJECTED TO RISE BY SLIGHTLY MORE THAN ONE PERCENTAGE POINT OVER PRIOR-YEAR FIGURE OF 28.2%.A DISORDERLY EXIT OF UNITED KINGDOM FROM EU AND AN EXACERBATION OF INTERNATIONAL TRADE DISPUTES COULD IMPACT SSB'S SUPPLY CHAIN TO A CERTAIN EXTENT, DESPITE MEASURES ALREADY TAKEN TO COUNTERACT THIS DEVELOPMEN.

Sartorius Stedim Biotech Q1 Sales Revenue Up 19.3% To 342.9 Million Euros

April 18 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::Q1 SALES REVENUE UP 19.3%; ORDER INTAKE UP 18.7%; EARNINGS MARGIN 28.6%.GUIDANCE FOR 2019 CONFIRMED.SALES REVENUE INCREASED AGAINST RELATIVELY MODERATE COMPARABLES IN THE PRIOR-YEAR QUARTER BY 19.3% TO 342.9 MILLION EUROS.Q1 ORDER INTAKE ALSO SAW A SIGNIFICANT UPTICK, RISING 18.7% TO 381.3 MILLION EUROS.Q1 UNDERLYING EBITDA1 ROSE OVERPROPORTIONATELY RELATIVE TO SALES BY 32.5% TO 98.1 MILLION EUROS.THE Q1 RESPECTIVE MARGIN REACHED 28.6% (Q1 2018: 26.3%).Q1 RELEVANT NET PROFIT AFTER NON-CONTROLLING INTEREST FOR THE GROUP SURGED BY 32.9% TO 62.6 MILLION EUROS.WE EXPECT THAT GROWTH RATES WILL NORMALIZE OVER THE COURSE OF THE YEAR. ON THIS BASIS WE CONFIRM OUR 2019 FULL-YEAR GUIDANCE - CEO.SEES CONSOLIDATED SALES REVENUE IS PROJECTED TO GROW BY ABOUT 7% TO 11% IN 2019.EXPECTS COMPANY'S UNDERLYING 2019 EBITDA MARGIN TO INCREASE BY SLIGHTLY MORE THAN ONE PERCENT.

Sartorius Stedim Biotech FY Revenue Up At 1.21 Billion Euros

Feb 19 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::FY SALES REVENUE ROSE IN CONSTANT CURRENCIES BY 13.7% TO 1,212.2 MILLION EUROS (REPORTED +12.1%)..SARTORIUS STEDIM BIOTECH EXPECTS CONTINUED PROFITABLE GROWTH IN 2019.WITHOUT THESE CHANGES, SALES GROWTH WOULD PROBABLY BE APPROXIMATELY 3 PERCENTAGE POINTS HIGHER..IN 2019, CONSOLIDATED SALES REVENUE IS PROJECTED TO GROW BY ABOUT 7% TO 11%.EBITDA MARGIN WILL INCREASE BY SLIGHTLY MORE THAN ONE PERCENTAGE POINT OVER THE PRIOR-YEAR FIGURE OF 28.2%.THE RATIO OF CAPITAL EXPENDITURES TO SALES REVENUE IS PROJECTED TO BE AROUND 11%, DOWN FROM YEAR-EARLIER FIGURE OF 14.6%..DISORDERLY EXIT OF THE UNITED KINGDOM FROM THE EU MAY HAVE A CERTAIN IMPACT ON OUR SUPPLY CHAIN.RELIABLE FORECAST OF POSSIBLE EFFECTS OF BREXIT CANNOT BE GIVEN AT THE PRESENT TIME.

Sartorius Stedim Biotech To Propose Dividend Of 0.57 Euro Per Share

Feb 8 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::SARTORIUS STEDIM BIOTECH: BOARD OF DIRECTORS RESOLVES TO PROPOSE DIVIDEND OF EUR 0.57 PER SHARE TO ANNUAL SHAREHOLDERS' MEETING.

Sartorius Stedim Biotech FY Double Digit Sales And Earnings Growth

Jan 29 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::SARTORIUS STEDIM BIOTECH GROWS BY DOUBLE DIGITS IN SALES AND EARNINGS IN 2018 – POSITIVE OUTLOOK FOR 2019.AMBITIOUS GUIDANCE FOR 2019 BACKED BY STRONG ORDER INTAKE.2018 GROUP SALES REVENUE UP 13.7%; EARNINGS MARGIN(1)) UP BY 0.9 PERCENTAGE POINTS TO 28.2%.

Lonza, Sartorius Modify Relationship For Supply Of Cell Culture Media

Nov 15 (Reuters) - Lonza And Sartorius Stedim Biotech Modify Relationship For Supply Of Cell Culture Media <LONN.S>::SARTORIUS STEDIM BIOTECH WILL CONTINUE TO OFFER LONZA MEDIA AND BUFFER PRODUCTS BUT UNDER A NON-EXCLUSIVE AGREEMENT.

Lonza Selects Sartorius Stedim Biotech As Preferred Supplier

Nov 15 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::SARTORIUS STEDIM BIOTECH AND LONZA MODIFY RELATIONSHIP FOR SUPPLY OF CELL CULTURE MEDIA.SARTORIUS STEDIM BIOTECH WILL CONTINUE TO OFFER LONZA MEDIA AND BUFFER PRODUCTS BUT UNDER A NON-EXCLUSIVE AGREEMENT.LONZA SELECTS SARTORIUS STEDIM BIOTECH AS PREFERRED SUPPLIER FOR EQUIPMENT AND CONSUMABLES.

Sartorius Stedim Biotech 9 Month Net Profit Rises To 160.7 Million Euros

Oct 23 (Reuters) - SARTORIUS STEDIM BIOTECH SA <STDM.PA>::9M GROUP SALES REVENUE UP 13.8%; ORDER INTAKE UP 14.5%; EARNINGS MARGIN 28.1%.2018 GUIDANCE CONFIRMED.FY SALES REVENUE GROWTH NOW PROJECTED TO BE IN UPPER RANGE OF PREVIOUSLY TARGETED BANDWIDTH OF 11% TO 14%.FY UNDERLYING EBITDA MARGIN CONTINUES TO BE EXPECTED AT AROUND 28.0%.9 MONTH NET PROFIT EUR 160.7 MILLION VERSUS EUR 130.8 MILLION YEAR AGO.9M UNDERLYING EBITDA 251.4 MILLION EUROS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up